Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the benzenesulfonamide class. It is primarily known as an experimental inhibitor of carbonic anhydrase II, a zinc metalloenzyme involved in the reversible hydration of carbon dioxide. The compound acts as a sulfonamide-based inhibitor and has been structurally characterized in complex with human carbonic anhydrase II. There are no approved therapeutic indications or clinical trials for this molecule, and it remains at the experimental research stage[1][7][8]. Its primary use is as a tool compound in biochemical studies of enzyme inhibition.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-({[(4-methylpiperazin-1-yl)amino]carbonothioyl}amino)benzenesulfonamide.